These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16247526)

  • 1. Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection.
    Gan SI; Devlin SM; Scott-Douglas NW; Burak KW
    Can J Gastroenterol; 2005 Oct; 19(10):625-9. PubMed ID: 16247526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of hepatitis B virus-associated membranous nephropathy with lamivudine.
    Okuse C; Yotsuyanagi H; Yamada N; Ikeda H; Takahashi H; Suzuki M; Kondo S; Kimura K; Koike J; Itoh F
    Clin Nephrol; 2006 Jan; 65(1):53-6. PubMed ID: 16429843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy.
    Chuang TW; Hung CH; Huang SC; Lee CM
    J Formos Med Assoc; 2007 Oct; 106(10):869-73. PubMed ID: 17964968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir.
    Das P; Vivek V; Ford M; Kingdon E; Holt S
    BMJ Case Rep; 2011 Aug; 2011():. PubMed ID: 22679045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Another case of HBV associated membranous glomerulonephritis resolving on lamivudine.
    Filler G; Feber J; Weiler G; Le Saux N
    Arch Dis Child; 2003 May; 88(5):460. PubMed ID: 12716731
    [No Abstract]   [Full Text] [Related]  

  • 6. Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection.
    Kanaan N; Horsmans Y; Goffin E
    Clin Nephrol; 2006 Mar; 65(3):208-10. PubMed ID: 16550752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy.
    Wen YK; Chen ML
    Clin Nephrol; 2006 Mar; 65(3):211-5. PubMed ID: 16550753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBV associated nephrotic syndrome: resolution with oral lamivudine.
    Connor FL; Rosenberg AR; Kennedy SE; Bohane TD
    Arch Dis Child; 2003 May; 88(5):446-9. PubMed ID: 12716723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine and HBV-associated nephropathy.
    Izzedine H; Massard J; Poynard T; Deray G
    Nephrol Dial Transplant; 2006 Mar; 21(3):828-9. PubMed ID: 16263733
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of lamivudine in the reactivation of hepatitis B virus infection in immunodepressed patients.
    Martín E; Rendón P; De Diego L; Soria MJ; Martínez MC; Martín L
    Rev Esp Enferm Dig; 2003 Nov; 95(11):804-8, 799-803. PubMed ID: 14640878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
    Ahmed A; Keeffe EB
    Am J Gastroenterol; 1999 Jan; 94(1):249-51. PubMed ID: 9934765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation.
    Ben-Ari Z; Broida E; Kittai Y; Chagnac A; Tur-Kaspa R
    Am J Gastroenterol; 2000 Dec; 95(12):3579-83. PubMed ID: 11151895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
    Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
    Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B viral infection with nephrotic syndrome treated with lamivudine.
    Banu NA; Khatoon S; Quadir E; Rahman MM; Khan MA
    Mymensingh Med J; 2007 Jul; 16(2):230-3. PubMed ID: 17703166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
    Song BC; Suh DJ; Lee HC; Chung YH; Lee YS
    Hepatology; 2000 Oct; 32(4 Pt 1):803-6. PubMed ID: 11003626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine therapy in acute leukemia patients who are hepatitis B surface antigen carriers.
    Yilmaz M; Dagdas S; Güler N; Aki SZ; Aköz AG; Özet G; Ayli M; Saritas U
    Hematology; 2003 Dec; 8(6):393-6. PubMed ID: 14668034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.
    Suzuki F; Tsubota A; Akuta N; Someya T; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Miyakawa Y; Kumada H
    J Gastroenterol; 2002; 37(11):922-7. PubMed ID: 12483247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation.
    Dai CY; Yu ML; Hsieh MY; Lee LP; Hou NJ; Huang JF; Chen SC; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY; Chuang WL
    Liver Int; 2007 Dec; 27(10):1364-70. PubMed ID: 17900250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.